Register
Login:
Share:
Email Facebook Twitter


Exclusive: Hayden Locke, CEO Emmerson plc, a low cost high margin potash investment
Richard Slape, Oil consultant - Avoiding Losers and Picking Winners, his personal strategy


ShareCast News


Synairgen broadens SNG001 trial after committee review

Thu, 14th Mar 2019 14:47


(Sharecast News) - Respiratory drug discovery and development company Synairgen announced on Thursday that its data safety monitoring committee had completed its planned safety review of the second part of the phase 2 clinical trial of its inhaled interferon-beta (IFN-beta) therapeutic candidate, SNG001, in patients with chronic obstructive pulmonary disease (COPD).

The AIM-traded firm said that in its review, the committee did not identify any safety concerns for patients currently enrolled in the second part of the trial.

As a result, it had endorsed a pre-planned broadening of the patient inclusion criteria, to allow patients with more severe COPD to participate in the trial.

"We welcome this decision from the data safety monitoring committee, as it aids trial recruitment and enables us to dose patients who have a higher medical need," said Synairgen chief executive officer Richard Marsden.

"COPD exacerbations are the second most common cause of unplanned hospital admission in England, and we are pleased to have the opportunity to develop SNG001 to include these high-risk patients prior to potential hospitalisation."


Related Shares:



Back to ShareCast News


Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk




Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.